SCHEDULE: Glen Taylor Boosts Envoy Medical Stake to 84.8%

Glen A. Taylor increased his beneficial ownership in Envoy Medical, Inc. to 84.8% through a $7.5 million stock and warrant purchase.

Summary

• Glen A. Taylor, the Reporting Person, filed an Amendment No. 1 to his Schedule 13D regarding Envoy Medical, Inc.
• On February 12, 2026, Taylor purchased 18,750,000 shares of Class A Common Stock and accompanying Common Warrants in an offering.
• The purchase included Series A-1 Warrants to buy 11,250,000 shares and Series A-2 Warrants to buy 18,750,000 shares.
• The combined offering price for each share of Class A Common Stock and accompanying Common Warrants was $0.40.
• The aggregate purchase price was $7,500,000, funded with personal funds.
• As of February 12, 2025, Taylor beneficially owns 68,909,614 shares of Class A Common Stock, representing 84.8% of the outstanding shares.
• This 84.8% ownership is based on 76,881,110 shares of Class A Common Stock outstanding immediately after the offering.
• The Common Warrants have an exercise price of $0.40 per share and become exercisable upon stockholder approval of the issuance of shares.
• Series A-1 Warrants expire on the earlier of 24 months post-Stockholder Approval Date or 30 days after Milestone 1.
• Series A-2 Warrants expire on the earlier of 60 months post-Stockholder Approval Date or 30 days after Milestone 2.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. A major insider significantly increasing their stake suggests strong conviction in the company's future, but the high concentration of ownership could impact liquidity and minority shareholder influence.

Positives

• A significant insider, Glen A. Taylor, increased his stake in Envoy Medical, Inc., demonstrating strong confidence in the company's future.
• The $7.5 million investment provides capital to the company, potentially supporting operations or strategic initiatives.
• The purchase was made at the same price and terms as other investors in the offering, indicating a fair market transaction.

Negatives

• The substantial increase in beneficial ownership by a single individual to 84.8% could reduce the public float and liquidity of the Class A Common Stock.
• High concentration of ownership may limit the influence of minority shareholders on corporate decisions.

Risks

• The exercisability of the Common Warrants is contingent on a future "Stockholder Approval Date," introducing a potential delay or uncertainty in the issuance of underlying shares.
• The expiration of Series A-1 and A-2 Warrants is tied to specific "Milestone 1" and "Milestone 2" events, which are not detailed in this filing, creating uncertainty regarding their terms.

Future Outlook

The exercisability of the Common Warrants is contingent upon a future "Stockholder Approval Date," and their expiration is tied to specific, undefined "Milestone 1" and "Milestone 2" events, indicating future corporate actions or performance targets will influence the full realization of the warrant value.

Industry Context

StockSavvy.ai notes that a significant increase in insider ownership, especially by a major shareholder like Glen A. Taylor, often signals strong internal confidence in the company's prospects, potentially differentiating Envoy Medical from competitors facing uncertain insider sentiment. This move could be interpreted as a defensive measure or a strategic consolidation of control, common in smaller or distressed companies where a single investor sees long-term value.

Comparison to Industry Standards

• This filing primarily details an insider's increased stake and a capital raise structure, rather than operational results. Therefore, direct comparisons to industry-standard operational metrics or project results are not applicable.
• StockSavvy.ai observes that an 84.8% beneficial ownership by a single individual is a very high concentration, significantly above typical institutional or founder ownership percentages in publicly traded companies, which often range from 5% to 30% for major shareholders. For example, while Elon Musk holds a substantial stake in Tesla (around 13%), and Mark Zuckerberg in Meta (around 13%), Glen Taylor's stake in Envoy Medical is considerably higher, indicating near-total control.

Corporate Governance

Stakeholder Impact

• Shareholders: Existing shareholders may see increased confidence due to insider buying, but also reduced liquidity and influence due to concentrated ownership. New investors in the offering participated on the same terms as the reporting person.
• Company: The company receives $7.5 million in capital from the offering, which can be used for operations or growth initiatives.

Next Steps

• The company will need to obtain "Stockholder Approval Date" for the issuance of shares upon exercise of the Common Warrants.
• The company will need to achieve "Milestone 1" and "Milestone 2" as defined in the Series A-1 and A-2 Warrants, respectively, which will impact the warrant expiration dates.

Key Dates

Recommendation

While the significant insider investment by Glen A. Taylor signals strong confidence and provides capital, the extremely high concentration of ownership (84.8%) could negatively impact liquidity and the influence of minority shareholders. This makes the stock less attractive for new investors seeking broad market participation or significant influence, but existing shareholders might see it as a vote of confidence. Therefore, a "hold" recommendation is appropriate, advising current investors to maintain their position while new investors should carefully consider the implications of such concentrated control.

Keywords

Envoy Medical, Glen A. Taylor, Schedule 13D, beneficial ownership, Class A Common Stock, warrants, insider buying, equity offering, SEC filing, corporate governance, investment